Associations Between Aldosterone Antagonist Therapy and Risks of Mortality and Readmission Among Patients With Heart Failure and Reduced Ejection Fraction | Zendy

Adrian F. Hernandez | Zendy; Xiaojuan Mi | Zendy; Bradley G. Hammill | Zendy; Stephen C. Hammill | Zendy; Paul A. Heidenreich | Zendy; Frederick A. Masoudi | Zendy; Laura G. Qualls | Zendy; Eric D. Peterson | Zendy; Gregg C. Fonarow | Zendy; Lesley H. Curtis | Zendy

Open Access

Associations Between Aldosterone Antagonist Therapy and Risks of Mortality and Readmission Among Patients With Heart Failure and Reduced Ejection Fraction

Author(s) -

Adrian F. Hernandez,

Xiaojuan Mi,

Bradley G. Hammill,

Stephen C. Hammill,

Paul A. Heidenreich,

Frederick A. Masoudi,

Laura G. Qualls,

Eric D. Peterson,

Gregg C. Fonarow,

Lesley H. Curtis

Publication year - 2012

Publication title -

jama

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 4.688

H-Index - 680

eISSN - 1538-3598

pISSN - 0098-7484

DOI - 10.1001/jama.2012.14795

Subject(s) - medicine , ejection fraction , heart failure , hazard ratio , hyperkalemia , cardiology , aldosterone , proportional hazards model , confidence interval

Aldosterone antagonist therapy for heart failure and reduced ejection fraction has been highly efficacious in randomized trials. However, questions remain regarding the effectiveness and safety of the therapy in clinical practice.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research